Otolaryngology Doctors in Littleton, CO Accepting Medicare

5 Otolaryngology doctors found. Showing 1 - 5

Dr. Carol Jeannette Langdoc, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 7851 S Elati St Ste 102, Littleton, CO 80120 Phone: 303-798-1309    Fax: 303-798-2319

Dr. Janice L Birney, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 6169 South Balsam Way, Suite 380, Littleton, CO 80123 Phone: 303-933-9050    Fax: 303-973-5616

Jeffrey Chain, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 7851 S Elati St Ste 102, Littleton, CO 80120 Phone: 303-798-1309    Fax: 303-798-2319

Sabrina Brody-camp, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1501 W Mineral Ave Ste 270, Littleton, CO 80120 Phone: 303-795-5587    Fax: 303-795-3404

Dr. Arvin Kumar Rao, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 15 W Dry Creek Cir, Littleton, CO 80120 Phone: 303-953-6767    Fax: 303-740-9311

News Archive

Hearing implants give best results when placed early

Investigators say that deaf children who are given cochlear implants before the age of 30 months are more able to combine what they hear and what they see than those who receive their implants when they are older.

Some anti-drinking campaigns catastrophically misconceived

Some anti-drinking advertising campaigns may be "catastrophically misconceived" because they play on the entertaining 'drinking stories' that young people use to mark their social identity, say researchers who have just completed a three year study of the subject.

MSKCC researchers study novel approach to treat metastatic melanoma

Physician-scientists at Memorial Sloan-Kettering Cancer Center are studying a novel approach to treat metastatic melanoma, known as immunotherapy, which uses the body's own immune system to attack cancer. Presented today at the American Society of Clinical Oncology annual meeting, encouraging new data shows - for the first time - a survival benefit in metastatic melanoma patients using an immunotherapy discovered and clinically investigated by researchers at Memorial Sloan-Kettering.

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

County-level sociodemographic risk factors associated with COVID-19 incidence and mortality

In just one year, COVID-19 has killed more than 400,000 Americans, and infected more than 24 million others. But a new study shows just how unevenly those deaths and cases have played out across the country.

Read more Medical News

› Verified 4 days ago